Applied DNA Sciences, Inc. announced the receipt of a follow-on order for Linea?? DNA valued above the mid-six figures. The order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) for a global manufacturer of in vitro diagnostics (IVD).

Under the terms of the repeat order, deliveries are expected to commence during the fiscal quarter ending March 31, 2024, through the fiscal quarter ending December 31, 2024. Linea DNA serves as an alternative to plasmid-based DNA that has been utilized in the manufacture of biotherapeutics for the past 40 years. Linea DNA is relevant to the next generation of nucleic acid-based therapies and diagnostics, including mRNA production, DNA vaccines, cell and gene therapies, as well as numerous veterinary medicine applications.